Uroxatral

Cysteine supplementation on top of the normal diet suggest by analogy: i ; that there is an ageing-related deficit in body cysteine and glutathione reservoirs and ii ; that a deficit in cysteine leads to a decrease in muscle function, a decrease in immune function, a decrease in plasma albumin concentration, and an increase in TNF-a concentration. As all these changes are hallmarks of the ageing process, it is concluded that the age-related decrease in body cysteine and or glutathione level may be a major driving force for multiple ageing-related degenerative processes. e ; Everybody is likely to experience a cysteine deficiency sooner or later As everybody beyond the fifth decade of life will experience sooner or later a decrease in muscle function, a decrease in immune function, a decrease in plasma albumin concentration, and or an increase in TNF-a concentration, it is hypothesized that practically everybody experiences sooner or later an ageingrelated deficit in the body cysteine and glutathione reservoirs that warrants cysteine supplementation. This hypothesis implies that ageing may be postponed and frailty be avoided to some extent by supplementation of the `paravitamin' cysteine. It is emphasized, however, that several details still require more systematic investigation. Although substantial negative side effects have not been observed in previous studies on cysteine supplementation, it is felt that the treatment protocols ought to be further improved to achieve maximum safety and efficacy over long periods of time. Properly done, cysteine supplementation can reasonably be expected to improve the quality of life in old age. With the availability of novel cysteine delivery systems with minimum amounts of calories, which are superior to any of the naturally available cysteine sources, it is conceivable that even the maximum human life span may be increased beyond the previous limit. Comparison of SCUs with non- Resident Status Measure Less staff time per resident in RSM ; , resident-care time, SCUs. Less cost for pts in SCU ward. Adjustment with case-mix due to differences in resource use wageSCUs but SCU pts have weighted for cost analysis ; . less comorbidities ; . When pts between wards. adjusted for case-mix: no or minimal difference in nursing costs between SCUs and non SCU units. Continuum of care program blending brief inpatient care with partial hospitalization ; vs. 21 day inpatient program CMAI modified ; , costbenefit analysis Both groups demonstrated improvement in CMAI to an equivalent degree with less cost with the continuum of care program. He World Health Organization WHO ; recommends that, in clinics where laboratory tests are not available, sexually transmitted infections STIs ; should be managed syndromically. That is to say, patients presenting with symptoms and clinical findings suggesting an STI should be treated for all the infections which commonly cause that clinical picture. WHO flowcharts are available for the syndromic management of urethral discharge and painful, swollen scrotum in males.
Bavituximab is a monoclonal antibody that, according to the sponsor, will bind to aminophospholipids on the exterior of cells that are either malignant or have been infected by a virus. It is currently in a phase I study of non-responders and relapsers to pegylated interferon plus ribavirin. Civacir is a polyclonal antibody made from human plasma and purified hepatitis C antibodies. After a FDA study of safety and pharmacokinetics in 18 HCV-infected liver transplant recipients, Civacir received Fast Track designation and Orphan Drug Status. Orphan Drug Status may be granted to products for conditions that affect less than 200, 000 people in the US. Orphan Drug Status has many benefits for the sponsor: tax incentives, financial and technical support for clinical trials, an exclusive market for seven years, and waived FDA user fees. A phase II proof-of-concept study in HCV-infected liver transplant recipients is slated for mid-to-late 2006. Results are expected in mid-2008. XTL-6865 is comprised of two monoclonal antibodies, Ab68 and Ab65. This combination replaced HepeX-C, a single Ab68 monoclonal antibody candidate. HepeX-C has been evaluated in a dose-ranging study and in HCV-infected transplant recipients in whom antiviral activity was established. A phase I study in people with chronic HCV is ongoing!

Where the child is already receiving prenatal care and has received a full medical evaluation, no report to CPS is indicated. If the minor is 14 years and older, physicians disclose results directly to the minor and assesses a ; whether the minor is already receiving prenatal care or pregnancy counseling, b ; whether minor's parent guardian is aware of the pregnancy, and c ; whether the pregnancy is a result of child sexual abuse. If a minor who is 14 years or older is already receiving prenatal health care, physicians confirm this with the local provider. No further referral or parental notification is necessary unless other examination findings meet the criteria for referral. If the minor is not receiving prenatal care, the physician discusses the importance of a medical evaluation and pregnancy counseling for the SP, and facilitates a referral. SPs with no source of care are referred to a local public health clinic or primary care provider. Because a parent guardian should be informed of a minor's pregnancy if she is not receiving prenatal care, the physician will offer to help the minor tell her parent guardian before leaving the MEC. If the minor strongly opposes the disclosure of the pregnancy test results to a parent or guardian, the physician respects the minor's confidentiality. 08918646IP, R.4 10 07 Doses should be taken at least 24 hours apart. Some men can only take a low dose of LEVITRA because of medical conditions or medicines they take. Your doctor will prescribe the dose that is right for you. If you are older than 65 or have liver problems, your doctor may start you on a lower dose of LEVITRA. If you have prostate problems or high blood pressure, for which you take medicines called alpha-blockers, your doctor may start you on a lower dose of LEVITRA. If you are taking certain other medicines your doctor may prescribe a lower starting dose and limit you to one dose of LEVITRA in a 72-hour 3 days ; period. Take 1 LEVITRA tablet about 1 hour 60 minutes ; before sexual activity. Some form of sexual stimulation is needed for an erection to happen with LEVITRA. LEVITRA may be taken with or without meals. Do not change your dose of LEVITRA without talking to your doctor. Your doctor may lower your dose or raise your dose, depending on how your body reacts to LEVITRA. If you take too much LEVITRA, call your doctor or emergency room right away. WHAT ARE THE POSSIBLE SIDE EFFECTS OF LEVITRA? The most common side effects with LEVITRA are headache, flushing, stuffy or runny nose, indigestion, upset stomach, or dizziness. These side effects usually go away after a few hours. Call your doctor if you get a side effect that bothers you or one that will not go away. LEVITRA may uncommonly cause: an erection that won't go away priapism ; . If you get an erection that lasts more than 4 hours, get medical help right away. Priapism must be treated as soon as possible or lasting damage can happen to your penis including the inability to have erections. color vision changes, such as seeing a blue tinge to objects or having difficulty telling the difference between the colors blue and green. In rare instances, men taking PDE5 inhibitors oral erectile dysfunction medicines, including LEVITRA ; reported a sudden decrease or loss of vision in one or both eyes. It is not possible to determine whether these events are related directly to these medicines, to other factors such as high blood pressure or diabetes, or to a combination of these. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including LEVITRA, and call a doctor right away. Sudden loss or decrease in hearing, sometimes with ringing in the ears and dizziness, has been rarely reported in people taking PDE5 inhibitors, including LEVITRA. It is not possible to determine whether these events are related directly to the PDE5 inhibitors, to other diseases or medications, to other factors, or to a combination of factors. If you experience these symptoms, stop taking LEVITRA and contact a doctor right away. These are not all the side effects of LEVITRA. For more information, ask your doctor or pharmacist. HOW SHOULD LEVITRA BE STORED? Store LEVITRA at room temperature between 59 and 86 F 15 Keep LEVITRA and all medicines out of the reach of children. GENERAL INFORMATION ABOUT LEVITRA. Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use LEVITRA for a condition for which it was not prescribed. Do not give LEVITRA to other people, even if they have the same symptoms that you have. It may harm them. This leaflet summarizes the most important information about LEVITRA. If you would like more information, talk with your healthcare provider. You can ask your doctor or pharmacist for information about LEVITRA that is written for health professionals. For more information you can also visit LEVITRA , or call 1-866-LEVITRA. WHAT ARE THE INGREDIENTS OF LEVITRA? Active Ingredient: vardenafil hydrochloride Inactive Ingredients: microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and red ferric oxide. Norvir ritonavir ; is a trademark of Abbott Laboratories Crixivan indinavir sulfate ; is a trademark of Merck & Co., Inc. Invirase or Fortavase saquinavir mesylate ; is a trademark of Roche Laboratories Inc. Reyataz atazanavir sulfate ; is a trademark of Bristol-Myers Squibb Company Nizoral ketoconazole ; is a trademark of Johnson & Johnson Sporanox itraconazole ; is a trademark of Johnson & Johnson Hytrin terazosin HCl ; is a trademark of Abbott Laboratories Flomax tamsulosin HCl ; is a trademark of Yamanouchi Pharmaceutical Co., Ltd. Cardura doxazosin mesylate ; is a trademark of Pfizer Inc. Minipress prazosin HCl ; is a trademark of Pfizer Inc. Uroxztral alfuzosin HCl ; is a trademark of Sanofi-Synthelabo and urispas.
Pierce, D.W., Hom-Booher, N., Otsuka, A.J., and Vale, R.D. 1999 ; . Single-molecule behavior of monomeric and heteromeric kinesins. Biochemistry 38, 54125421. Pike, L.J., and Casey, L. 1996 ; . Localization and turnover of phosphatidylinositol 4, 5-bisphosphate in caveolin-enriched membrane domains. J. Biol. Chem. 271, 2645326456. Pollock, N., Koonce, M.P., de Hostos, E.L., and Vale, R.D. 1998 ; . In vitro microtubule-based organelle transport in wild-type Dictyostelium and cells overexpressing a truncated dynein heavy chain. Cell Motil. Cytoskeleton 40, 304314. Pollock, N., de Hostos, E.L., Turck, C.W., and Vale, R.D. 1999 ; . Reconstitution of membrane transport powered by a novel dimeric kinesin motor of the Unc104 KIF1A family purified from Dictyostelium. J. Cell Biol. 147, 493506. Pralle, A., Keller, P., Florin, E.L., Simons, K., and Horber, J.K. 2000 ; . Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J. Cell Biol. 148, 9971008. Reilein, A.R., Rogers, S.L., Tuma, M.C., and Gelfand, V.I. 2001 ; . Regulation of molecular motor proteins. Int. Rev. Cytol. 204, 179238. Rogers, K.R., Weiss, S., Crevel, I., Brophy, P.J., Geeves, M., and Cross, R. 2001 ; . KIF1D is a fast non-processive kinesin that demonstrates novel K-loop-dependent mechanochemistry. EMBO J. 20, 51015113. Sakowicz, R., Farlow, S., and Goldstein, L.S. 1999 ; . Cloning and expression of kinesins from the thermophilic fungus Thermomyces lanuginosus. Protein Sci. 8, 27052710. Sandhoff, R., Brugger, B., Jeckel, D., Lehmann, W.D., and Wieland, F.T. 1999 ; . Determination of cholesterol at the low picomole level by nano-electrospray ionization tandem mass spectrometry. J. Lipid Res. 40, 126132. Schroer, T.A., and Sheetz, M.P. 1991 ; . Two activators of microtubule-based vesicle transport. J. Cell Biol. 115, 13091318. Sheetz, M.P. 1999 ; . Motor and cargo interactions. Eur. J. Biochem. 262, 1925. Simons, K., and Ikonen, E. 1997 ; . Functional rafts in cell membranes. Nature 387, 569572. Taunton, J., Rowning, B.A., Coughlin, M.L., Wu, M., Moon, R.T., Mitchison, T.J., and Larabell, C.A. 2000 ; . Actin-dependent propulsion of endosomes and lysosomes by recruitment of N-WASP. J. Cell Biol. 148, 519530. Toker, A. 1998 ; . The synthesis and cellular roles of phosphatidylinositol 4, 5-bisphosphate. Curr. Opin. Cell Biol. 10, 254261. Vale, R.D., and Fletterick, R.J. 1997 ; . The design plan of kinesin motors. Annu. Rev. Cell Dev. Biol. 13, 745777. Vale, R.D., and Milligan, R.A. 2000 ; . The way things move: looking under the hood of molecular motor proteins. Science 288, 8895. Van der Kaay, J., Draijer, R., and Van Haastert, P.J. 1990 ; . Increased conversion of phosphatidylinositol to phosphatidylinositol phosphate in Dictyostelium cells expressing a mutated ras gene. Proc. Natl. Acad. Sci. USA 87, 91979201. van Heyningen, W.E., and King, C.A. 1976 ; . The role of gangliosides in the action of cholera toxin. Adv. Exp. Med. Biol. 71, 205214. Varma, R., and Mayor, S. 1998 ; . GPI-anchored proteins are organized in submicron domains at the cell surface. Nature 394, 798801. Wang, J., Arbuzova, A., Hangyas-Mihalyne, G., and McLaughlin, S. 2001 ; . The effector domain of myristoylated alanine-rich C kinase substrate binds strongly to phosphatidylinositol 4, 5-bisphosphate. J. Biol. Chem. 276, 50125019. Yonekawa, Y., Harada, A., Okada, Y., Funakoshi, T., Kanai, Y., Takei, Y., Terada, S., Noda, T., and Hirokawa, N. 1998 ; . Defect in synaptic vesicle precursor transport and neuronal cell death in KIF1A motor protein-deficient mice. J. Cell Biol. 141, 431441. Zhou, H.M., Brust-Mascher, I., and Scholey, J.M. 2001 ; . Direct visualization of the movement of the monomeric axonal transport motor UNC-104 along neuronal processes in living Caenorhabditis elegans. J. Neurosci. 21, 37493755. Uroxatral alfuzosin hcl extended-release tablets ; the change in heart rate with moxifloxacin was 8 beats minut what are the possible side effects of uroxatral and casodex. In today's exercise, we will be creating a fusion protein of our very hour, by joining together the nucleotide sequence of the human pleckstrin gene to bacterial GST to the jellyfish gene for green fluorescent protein GFP ; . GFP is a nifty tag since it literally causes the regions where the fusion protein is expressed to "light up." Really. You will be doing this process backwards. Namely, given some data from the DNA sequence encoding this fluoreckstrin fusion protein FP ; which I will e-mail out to you so you don't have to type it in, you will determine the order of the three DNA fragments used to construct it and the identity of the restriction sites used for that construction. Physiologic responses to pain are increased heart rate, increased respiration rate, fever, hypertension, dilated pupils, and increased cortisol levels. 30 Physiologic responses may not be an adequate indication by themselves and should not be relied on as a sole indicator. 1 An anthropomorphic approach should be used if the caregiver has difficulty interpreting behavioral characteristics associated with a situation known to cause pain. 3 This approach involves providing appropriate analgesics for the level of pain likely to be present and providing treatment based on predicted level of pain even if outward signs of pain are not present. 3 Regardless of the clinical signs demonstrated, if there is any doubt that an animal may be experiencing pain, then a trial treatment with analgesics may be indicated. At times, response to analgesic treatment may be the most reliable gauge of the patient's pain. 1 Veterinarians and veterinary technicians should be familiar with normal physiologic values and behaviors and evaluate patients non-interactively and interactively. They should perform serial assessments to document changes in pain status and response to treatment. It may be best if the same person does all assessments to avoid variations between observers. Assess all patients for presence and intensity of pain or distress. Record results in a manner which allows for easy reassessment and follow up. 1 A universal pain score is recommended to facilitate communication between staff members and professionals throughout the veterinary community and ultracet. Uroxatral should not be administered with potent cyp3a4 inhibitors and therefore should not be used in combination with drugs such as ketoconazole, itraconazole or ritonavir. Tricare Press Release - On January 10, the DoD Beneficiary Advisory Panel BAP ; met to review DoD proposals to elevate some cardiovascular disorder, prostate, and immune disease medications to the third tier, or copay level. In the cardiovascular disorder category, the BAP concurred with keeping Zebeta, Coreg, Toprol XL, and Lopressor at or copays. Within the prostate medications, DoD proposed a "prior authorization" requirement which would require beneficiaries to try Uroxxtral before Hytrin, Cardura, or Flomax unless they had a current prescription within the last 180 days. Even after trying Urkxatral without success, a "medical necessity" statement from a physician is still needed for Flomax or beneficiaries would have to pay a copay. The BAP agreed to the prior authorization requirement but urged DoD to move Flomax back to a lower copay. The targeted immunomodulatory biologics TIB ; -- Enbrel, Kineret, Humira, Raptiva, and Amevive -- are used to treat various forms of arthritis, psoriasis, Chron's Disease, and ulcerative colitis. By a one-vote margin, the BAP concurred with moving Enbrel and Kineret to the third tier but recommended delaying implementation for 120 days to allow time for patients to consult with their doctor and a rheumatologist. The BAP agreed to move Exforge, a combination drug for high blood pressure, and the contraceptive Lybrel to the third tier with a 60-day implementation period. However, the BAP did not concur with moving Vyvnase, used to treat ADHD, to a copay. This is the first case where DoD has recommended third tier status when there was no clinically meaningful therapeutic disadvantage or cost advantage. The BAP concurred with DoD's recommendations to place the generic version of the hypertension drug Norvasc back on the formulary at a lower copay than the current price. All recommendations will be submitted to the Assistant Secretary of Defense Health Affairs ; for final decision. Beneficiaries can use the Formulary Search Tool located on TRICARE's pharmacy web site : tricare l mybenefit home Prescriptions for additional information about medications, their availability and cost and lioresal.

Carteolol hcl levobunolol hcl pilocarpine hcl timolol maleate ALPHAGAN P COSOPT LUMIGAN TRUSOPT XALATAN 14.6 OTHER OPHTHALMIC DRUGS cromolyn sodium ACULAR, -LS, -PF PATANOL RESTASIS VOLTAREN CHAPTER 15: RESPIRATORY MEDICATIONS 15.1.1 BETA-2 ADRENERGIC DRUGS albuterol, -sulfate FORADIL SEREVENT DISKUS VENTOLIN HFA XOPENEX HFA tier 3 ; XOPENEX soln tier 3 ; 15.1.2 METHYL XANTHINE DRUGS theophylline, anhydrous UNIPHYL 15.1.3 OTHER DRUGS FOR ASTHMA ipratropium bromide ADVAIR DISKUS ATROVENT, HFA COMBIVENT DUONEB EPIPEN, -JR. FLOVENT HFA INTAL PULMICORT SPIRIVA TILADE 15.1.4 LEUKOTRIENE MODIFIERS SINGULAIR step therapy ; 15.2.1 ANTIHISTAMINES cyproheptadine hcl promethazine hcl ZYRTEC tier 3 ; ZYRTEC SYRUP tier 2, only age 12, derm only ; 15.2.3 ANTIHISTAMINE DECONGESTANT COMBINATIONS promethazine vc ZYRTEC-D tier 3 ; 15.3 ANTITUSSIVE AND EXPECTORANT DRUGS benzonatate guaifenesin w codeine guaifenex pse hydrocodone w guaifenesin promethazine vc w codeine promethazine w codeine promethazine w dm TUSSIONEX CHAPTER 16: UROLOGICAL MEDICATIONS 16.1.1 ANTICHOLINERGIC ANTISPASMODICS oxybutynin chloride DETROL, -LA DITROPAN XL 16.1.3 URINARY ANESTHETICS phenazopyridine hcl 16.1.4 OTHER GENITOURINARY PRODUCTS FLOMAX PROSCAR UROXATRAL CHAPTER 17: DIAGNOSTIC & MISC MEDICATIONS Not applicable to formulary CHAPTER 18: MEDICAL MISCELLANEOUS ; SUPPLIES 18.1 DIABETIC SUPPLIES Limit of 205 rx ACCU-CHEK all products ; CHEMSTRIP BG all products ; FAST TAKE all products ; ONE TOUCH all products ; SURESTEP all products. Ohio Clean Energy Business Association Columbus, Ohio Green Energy Ohio ; Ohio Clean Energy Business Association OCEBA ; was formed in 2003 by ten Ohio firms engaged in the "clean energy" business. Its purpose is to grow a diverse, sustainable energy economy that improves the quality of life for Ohio residents. The association focuses on educating the public, businesses, and legislators while promoting concise policy changes that stimulate renewable energy growth. Its latest report, released in April 2005, concerns the implications of Ohio Non-Attainment i.e., air pollution levels that exceed the federal air quality standards ; . OCEBA has campaigned to promote the economic benefits of the wind power industry, including job creation and research opportunities. West Michigan Sustainable Business Forum Grand Rapids, Michigan Contact: Bill Stough. The West Michigan Sustainable Business Forum seeks a "triple bottom-line objective": to promote business practices that demonstrate environmental stewardship, economic vitality, and social responsibility. Its membership includes large area industries, particularly furniture and textile manufacturers, and small businesses. The SBF helps companies share information about waste reduction, renewable materials, energy conservation, and "best practices." Founded in 1994 under the auspices of the West Michigan Environmental Action Council, the forum has not taken policy positions and zanaflex. Dr. Crook, president of the International Health Foundation, has tried to report all the possibilities behind the syndrome, as well as information he collects from physicians and patients who have dealt with the Candida problem. It is important to note that his book does not carry all the information behind the syndrome and opinions may vary among the doctors treating it, as research in the syndrome is continuing. Symptoms As listed in Dr. Crook's books, The Yeast Connection and The Yeast Connection and the Woman: Please note that these symptoms may seem vast and broad ranging. It is the presence of multiple symptoms and not a single symptom that may be an indicator of candidiasis. The following symptoms from Dr. Crook's book have gone beyond what research has commonly shown symptoms of candidiasis to be to provide a broader range of possibilities. Please note the references to medical studies and the list of most common symptoms of candidiasis following Dr. Crook's list if this information is not to be used for experimental purposes. Familial retinal arteriolar tortuosity with superficial macular hemorrhages was first reported by Beyer in 1958.1 Since that original report, other families have been identified in Europe, North America, and Japan.2-11 These cases, like ours, are characterized by arteriolar tortuosity, competency of the retinal vessels on fluorescein angiography, intermittent superficial retinal hemorrhages, and autosomal dominant transmission. Venules are normal. The and skelaxin.
Fig. 4. Effects of theophylline at 10-4 M T4 ; and 10-5 M T5 ; , and 0.510-8 M isoproterenol I ; or both on platelet-activating factor PAF and neuinduced L-selectin downregulation on eosinophils trophils ; . Incubation with T4 T5 and or I was performed in whole blood prior to PAF 10-7 M ; . Results are presented as mean percentagesSD compared to stimulation with PAF alone % PAF ; n 24 ; . The effect of theophylline or isoproterenol was significantly different p 0.05 ; from the effect of PAF alone * ; and from the effect of PAF and isoproterenol. Cyclo-oxygenase-2 COX-2 ; selective inhibitors, which only inhibit COX-2 and not COX-1 at therapeutic doses, have been developed. Several studies have shown that they provide efcacy similar to conventional NSAIDs, but with improved safety and tolerability.1114 However, until now, COX-2 selective inhibitors have only been available as oral formulations, which many patients may be unable to take, especially in the perioperative period. Parecoxib sodium is the rst parenteral form of a COX-2 selective inhibitor developed for acute pain. It is an amide pro-drug that is rapidly hydrolysed in vivo to the active form, valdecoxib, a COX-2 selective inhibitor with a COX-2: COX-1 selectivity ratio of approximately 28 000: 1. Clinical studies have and tegretol and Order uroxatral.
Patients with Congenital or Acquired QT Prolongation: In a study of QT effect in 45 healthy males See CLINICAL PHARMACOLOGY, Electrophysiology ; , the QT effect appeared less with alfuzosin 10 mg than with 40 mg, and the effect of alfuzosin 40 mg did not appear as large as that of the active control moxifloxacin at its therapeutic dose. This observation should be considered in clinical decisions to prescribe UROXATRAL for patients with a known history of QT prolongation or patients who are taking medications known to prolong QT, although there has been no signal of Torsades de Pointe in the extensive postmarketing experience with alfuzosin outside the United States. There are no known PK PD studies of the effects of other alpha blockers on cardiac repolarization.
Figure 7 -- Mean Change from Baseline in Peak Urine Flow Rate ml s ; , by Visit: Study 3 Mean total IPSS decreased at the first scheduled observation at Day 28 and mean peak flow rate increased starting at the first scheduled observation at Day 14 in studies 2 and 3 and Day 28 in study 1. INDICATIONS AND USAGE UROXATRAL alfuzosin HCl extended-release tablets ; is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension and baclofen. Uroxatral has been in use in europe for over 16 years, and now it'savailable in the us.
Selling well, within the newly shrunken market Bicycling World, 26 February 1903, 642 ; . And Bicycling World's editors explicitly supported high profit margins 26 March 1903, 765, 766 ; . But the argument that the entire industry consciously pursued a high-margin, low-volume basis is insufficient. The opposite strategy--high volume and low margins--might have worked, considering that the working class was expanding quickly and commuting was already occurring. Price and weight were inversely proportional; a redesigned, heavy, but sturdy i.e., "high quality" ; bicycle might have been inexpensive to produce--it might even have had decent profit margins--and would have sold in the millions. This did not happen. A far better explanation than high margins is that the industry as a whole suffered from what Leavitt 1960 ; called "marketing myopia." In this period 1890-1910 ; , most marketing and advertising in all American industries was approved by owner-manufacturers themselves. Businessmen usually ran ads that mirrored their own class status. They judged advertising according to their own tastes, assumed that others' reactions paralleled their own, and therefore projected their own interests onto the world. They did not learn how others lived or how others felt about or used their products Laird 1998, 91-94, 97-98, ; . In its inability to see the new, working-class market, members of the bicycle industry seem trapped inside their own view of the world, unable to adjust to new conditions and a new set of consumers. Most people in the industry clearly wanted to expand the bicycle market. Throughout the decade 1901-1910, Bicycling World repeatedly ran articles suggesting how to increase "the trade" in bicycles, and letters to the editor repeatedly responded to them. The only mention of the possibility of a "utility" market appeared at the end of a 1901 page-long article on "why the trade collapsed." This last paragraph suggested that the subject of practical riding "[was] a much vaster one . whose consideration is deferred until another time" Bicycling World, 29 August 1901, 441 ; . 40.